InflaRx to Present at Upcoming Investor Conferences
03 mars 2021 07h30 HE
|
InflaRx N.V.
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will present at...
InflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year Warrants
01 mars 2021 16h01 HE
|
InflaRx N.V.
JENA, Germany, March 01, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement...
InflaRx Announces Pricing of $75 Million Public Offering of Common Shares and One-Year Warrants
25 févr. 2021 08h30 HE
|
InflaRx N.V.
JENA, Germany, Feb. 25, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Announces Proposed Offering of Common Shares and One-Year Warrants
24 févr. 2021 16h01 HE
|
InflaRx N.V.
JENA, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation Conference
11 févr. 2021 07h30 HE
|
InflaRx N.V.
Significantly elevated baseline C5a levels occur in hidradenitis suppurativa (HS) patientsVilobelimab dose-dependently suppresses C5a levels over time accompanied by the previously reported reduction...
InflaRx Provides Update on Vilobelimab (IFX-1) Development
11 janv. 2021 07h30 HE
|
InflaRx N.V.
Multiple data readouts expected in 2021Phase II trial in patients with cutaneous squamous cell carcinoma expected to start in the first half of 2021 JENA, Germany, Jan. 11, 2021 (GLOBE...
InflaRx to Present at Upcoming Annual J.P. Morgan Healthcare Conference
07 janv. 2021 07h30 HE
|
InflaRx N.V.
JENA, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis
05 janv. 2021 07h30 HE
|
InflaRx N.V.
JENA, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Reports Q3 2020 Financial & Operating Results
29 oct. 2020 07h00 HE
|
InflaRx N.V.
Initiated Phase III part of the Phase II/III adaptive, randomized, controlled trial in patients with severe COVID-19 induced pneumoniaPublished encouraging data from Phase II part of COVID-19 trial in...
InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer
17 sept. 2020 07h30 HE
|
InflaRx N.V.
Thomas Taapken, Ph.D. appointed Chief Financial OfficerJordan Zwick promoted to Chief Strategy Officer JENA, Germany, Sept. 17, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage...